MDS & Myeloproliferative Neoplasms

MDS & Myeloproliferative Neoplasms

A collection of features and news articles published in ASH Clinical News related to myelodysplastic syndromes and myeloproliferative neoplasms.

Five Decades of Experience With MPNs: Characterizing Survival and Outcomes

A report based on data from more than 3,000 patients with myeloproliferative neoplasms (MPNs) evaluated at the Mayo Clinic in Rochester, Minnesota, over 50...

The Year in FDA Approvals

In the past year, the U.S. Food and Drug Administration (FDA) approved several therapies for the treatment of myeloid malignancies, including the first treatment...

Non-Engineered T Cells to Prevent or Treat Relapse in Post-Transplant AML/MDS

Infusion with “non-engineered” adoptive T-cell products induced responses in select patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) who had undergone allogeneic...

CHIP-Associated Mutations Linked With Comorbidities in MDS

The presence of clonal hematopoiesis of indeterminate potential (CHIP) mutations, particularly DNMT3A and JAK2 mutations, was associated with a higher likelihood of prior myocardial...

A Safer Conditioning Regimen for Patients With Bone Marrow Failure and Short Telomeres?

A study of patients with bone marrow failure (BMF) and short telomeres found that a conditioning regimen that eliminates radiation and DNA-alkylating agents led...

The significance of JAK2-positive test results in a healthy patient

This month Josef Prchal, MD, discusses the significance of JAK2-positive test results in a healthy patient. And don't forget to check out next month's clinical dilemma...

The significance of JAK2-positive test results in a healthy patient

Here’s how readers responded to a You Make the Call question about the significance of JAK2-positive test results in a healthy patient. Disclaimer: ASH does...

Tagraxofusp-erzs Becomes First Approval for BPDCN

The U.S. Food and Drug Administration approved tagraxofusp-erzs for the treatment of adults and children (≥2 years of age) with blastic plasmacytoid dendritic cell...

Transplant or No Transplant for Older, Fit Patients With MDS?

Hematopoietic cell transplantation (HCT) with reduced-intensity conditioning improved overall survival (OS) in older patients with advanced myelodysplastic syndromes (MDS), compared with OS in patients...

An MRD-Guided Azacitidine Treatment Strategy Delays Hematologic Relapse in MDS and AML

According to results from the phase II RELAZA2 trial, minimal residual disease (MRD)–guided treatment with the hypomethylating agent azacitidine delayed hematologic relapse in patients...
Advertisement

Current Issue

May 2019, Volume 5, Issue 6

This issue features a look at home-based care for hematologic disorders, strides in pediatric leukemia in El Salvador, and more.